EZ Cap™ Human p53 mRNA (ψUTP)
p53 is one of the most studied transcription factors. p53 can activate its downstream genes in response to carcinogenic signals, such as apoptosis promoting protein BAX, p53 upregulates apoptosis regulator PUMA, etc. p53 also acts as a cell cycle checkpoint protector to induce cell cycle arrest and participate in DNA replication and repair to protect genomic integrity.
EZ Cap™ Human p53 mRNA (ψUTP) is provided at a concentration of ~1 mg/ml with Cap1 structure. There are currently two ways to cap mRNA: One is co-transcription method, by adding Cap analogues into the transcription process. The other is enzymatic Capping. After transcription, Cap0 capping is performed by Vaccinia virus Capping Enzyme (VCE), GTP and S-adenosylmethionine (SAM). The Cap0 is then generated into the Cap1 through 2´-O-Methyltransferase and SAM. Cap1 Capping can also be performed by adding VCE, 2´-O-Methyltransferase, GTP and SAM in a one-step process. Cap 1 structure is more ideal for mammalian systems and possess higher transcription efficiency than Cap 0 structure. The addition of ψUTP and poly(A) tail suppress RNA-mediated innate immune activation and increase the stability and lifetime of the mRNA in vitro and in vivo. Poly(A) tail also plays an important role in enhancing the efficiency of translation initiation.
| mRNA Length | 1437 nucleotides |
| Concentration | 1 mg/mL |
| Buffer | 1 mM Sodium Citrate, pH 6.4 |
| Storage | -40°C or below |
| General tips | Please dissolve it on ice and protect from RNase carefully. Avoid repeated freeze/thaw cycles as possible. Don’t vortex. Upon first use, centrifuge the tube softly and aliquot it into several single use portions. Use RNase-free reagents and materials with appropriate RNase-free technique. Don’t add to the media with serum unless mixing with a transfection reagent. |
| Shipping Condition | ship with dry ice |
- 1. Yan Liang, Chenlu Xu, et al. "Simultaneously supplementing Wtp53 and degrading Mutp53 using a virus-mimicking mRNA delivery system to restore P53's autonomous anti-cancer function." Nano Research Volume 18 Issue 6, June 2025
- 2. Yan Liang, Jingge Zhang, et al. "Restoring Tumor Cell Immunogenicity Through Ion-Assisted p53 mRNA Domestication for Enhanced In Situ Cancer Vaccination Effect." Adv Sci (Weinh). 2025 Apr;12(14):e2500825
It can be based on your experimental goals:
- For Tracking Transfection and Translation Efficiency: APExBIO Reporter Gene mRNAs (e.g. EGFP, Firefly Luciferase mRNA) are commonly used to track transfection efficiency and protein expression duration; evaluate gene expression and cell viability; study mRNA localization and bio-distribution via in vivo imaging; optimize transfection conditions and validate LNP delivery system.
- For Gene Editing, Functional Studies and Gene Therapy Research: APExBIO offers various functional protein mRNAs, involving tumor suppressors (e.g. p53, PTEN), cytokines (e.g. IL-12, IL-10), gene-editing tools (e.g. spCas9, Cre Recombinase), gene replacement protein (e.g. EPO), and antigens (e.g. OVA, SARS-CoV-2 Spike).
- For Sustained Protein Expression: APExBIO Self-amplifying RNA (saRNA) and Circular RNA (circRNA) are recommended for applications requiring prolonged protein expression. saRNA enables lasting and strong protein expression at lower doses, while circRNA has enhanced structural stability and extended expression duration.
- Advanced Capping Technology: Utilizes Cap 1 structure (EZ Cap™ Cap) to achieve enhanced translation efficiency and minimizing activation of the host innate immune response. The capping efficiency can reach 90–99%.
- Diverse Modification Options: Provides a range of modified nucleotides, such as m1Ψ B8049, 5-moUTP B8061 and Cy5-UTP B8333, which reduce immunogenicity, improve mRNA stability, and maximize protein expression levels.
- Stringent Quality Control: Each batch undergoes rigorous quality assessment including capping efficiency, purity, integrity, and sterility to ensure batch-to-batch consistency.
